FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282946249> ?p ?o ?g. }

• W4282946249 endingPage "5477" @default.
• W4282946249 startingPage "5477" @default.
• W4282946249 abstract "Abstract The L858R activating mutation in Epidermal Growth Factor Receptor (EGFR) accounts for approximately 40% of EGFR-mutant non-small cell lung cancer (NSCLC). These patients receive targeted therapy targeting EGFR mutation. To date all approved EGFR tyrosine kinase inhibitors (TKIs) are ATP competitive inhibitors, inevitably lead to drug resistance and to disease progress. Osimertinib is a third-generation EGFR TKI that selectively inhibits both EGFR TKI-sensitizing (L858R) mutation and T790M mutation that confers acquired resistance to first- and second-generation EGFR-TKIs. The patients develop secondary resistance L858R/C797S and L858R/T790M/C797S to this treatment in some cases. There have been strong unmet needs for specific therapies targeting C797S resistance mutations. Additionally, toxicities caused by inhibition of wild-type (WT) EGFR are frequently reported with the first-generation inhibitors (e.g. Gefitinib and Erlotinib). Our Compound A is a highly mutant-selective fourth-generation allosteric inhibitor that targets L858 activating mutations and without affecting EGFR WT that compares favorably with all ATP competitive inhibitors, indicating that it might avoid potential toxicities from targeting EGFR WT. Compound A has a single-digit nanomolar potency against L858R activating mutation and those harboring T790M and C797S resistance mutations. Oral administration of Compound A to tumor-bearing mice showed significant antitumor activity as a single-agent at well-tolerated doses via inhibiting EGFR pathway in the engineered osimertinib-resistance EGFRL858R/T790M/C797S and EGFRL858R/C797S CDX models. Furthermore, Compound A demonstrated excellent efficacy in EGFRL858R/T790M CDX model as a single-agent. Collectively, Compound A has a robust potency against L858R activating mutations including T790M, C797S, and T790M/C797S that cause acquired resistance to ATP competitive EGFR TKIs in vitro and in vivo. Based on the preclinical data, Compound A is a potent, orally available, and mutant-selective fourth-generation allosteric inhibitor of EGFR with L858R activating mutations for the treatment of NSCLC, suggesting that it might have the potential to demonstrate activity in the first line and resistance settings as a single agent. The pre-clinical data described here supports the clinical development of Compound A in NSCLC patients with L858R activating mutations of EGFR. Citation Format: Yeji Byeon, Seung Hee Jung, Daseul Yoon, Seock Yong Kang, Jiyeon Park, Hyeim Jo, Seong-Il Choi, Somyi Park, Seung-chul Lee, Yang Hun Tae, Tae Min Kim, Sung-Yup Cho, Soyeon Kim, Donghyun Ko, Dong-Kyu Kim, Dong-Wan Kim. Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5477." @default.
• W4282946249 created "2022-06-16" @default.
• W4282946249 creator A5019037704 @default.
• W4282946249 creator A5019251044 @default.
• W4282946249 creator A5020952516 @default.
• W4282946249 creator A5028969525 @default.
• W4282946249 creator A5032743380 @default.
• W4282946249 creator A5037369509 @default.
• W4282946249 creator A5039995396 @default.
• W4282946249 creator A5053052938 @default.
• W4282946249 creator A5057456595 @default.
• W4282946249 creator A5058521062 @default.
• W4282946249 creator A5062356396 @default.
• W4282946249 creator A5068033934 @default.
• W4282946249 creator A5079484363 @default.
• W4282946249 creator A5085681049 @default.
• W4282946249 creator A5089677315 @default.
• W4282946249 creator A5089973425 @default.
• W4282946249 date "2022-06-15" @default.
• W4282946249 modified "2023-10-07" @default.
• W4282946249 title "Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC" @default.
• W4282946249 doi "https://doi.org/10.1158/1538-7445.am2022-5477" @default.
• W4282946249 hasPublicationYear "2022" @default.
• W4282946249 type Work @default.
• W4282946249 citedByCount "0" @default.
• W4282946249 crossrefType "journal-article" @default.
• W4282946249 hasAuthorship W4282946249A5019037704 @default.
• W4282946249 hasAuthorship W4282946249A5019251044 @default.
• W4282946249 hasAuthorship W4282946249A5020952516 @default.
• W4282946249 hasAuthorship W4282946249A5028969525 @default.
• W4282946249 hasAuthorship W4282946249A5032743380 @default.
• W4282946249 hasAuthorship W4282946249A5037369509 @default.
• W4282946249 hasAuthorship W4282946249A5039995396 @default.
• W4282946249 hasAuthorship W4282946249A5053052938 @default.
• W4282946249 hasAuthorship W4282946249A5057456595 @default.
• W4282946249 hasAuthorship W4282946249A5058521062 @default.
• W4282946249 hasAuthorship W4282946249A5062356396 @default.
• W4282946249 hasAuthorship W4282946249A5068033934 @default.
• W4282946249 hasAuthorship W4282946249A5079484363 @default.
• W4282946249 hasAuthorship W4282946249A5085681049 @default.
• W4282946249 hasAuthorship W4282946249A5089677315 @default.
• W4282946249 hasAuthorship W4282946249A5089973425 @default.
• W4282946249 hasConcept C104317684 @default.
• W4282946249 hasConcept C121608353 @default.
• W4282946249 hasConcept C126322002 @default.
• W4282946249 hasConcept C156719811 @default.
• W4282946249 hasConcept C182707283 @default.
• W4282946249 hasConcept C185592680 @default.
• W4282946249 hasConcept C2777506169 @default.
• W4282946249 hasConcept C2777626846 @default.
• W4282946249 hasConcept C2777930144 @default.
• W4282946249 hasConcept C2778087573 @default.
• W4282946249 hasConcept C2779438470 @default.
• W4282946249 hasConcept C2780580887 @default.
• W4282946249 hasConcept C502942594 @default.
• W4282946249 hasConcept C55493867 @default.
• W4282946249 hasConcept C67705224 @default.
• W4282946249 hasConcept C71924100 @default.
• W4282946249 hasConcept C98274493 @default.
• W4282946249 hasConceptScore W4282946249C104317684 @default.
• W4282946249 hasConceptScore W4282946249C121608353 @default.
• W4282946249 hasConceptScore W4282946249C126322002 @default.
• W4282946249 hasConceptScore W4282946249C156719811 @default.
• W4282946249 hasConceptScore W4282946249C182707283 @default.
• W4282946249 hasConceptScore W4282946249C185592680 @default.
• W4282946249 hasConceptScore W4282946249C2777506169 @default.
• W4282946249 hasConceptScore W4282946249C2777626846 @default.
• W4282946249 hasConceptScore W4282946249C2777930144 @default.
• W4282946249 hasConceptScore W4282946249C2778087573 @default.
• W4282946249 hasConceptScore W4282946249C2779438470 @default.
• W4282946249 hasConceptScore W4282946249C2780580887 @default.
• W4282946249 hasConceptScore W4282946249C502942594 @default.
• W4282946249 hasConceptScore W4282946249C55493867 @default.
• W4282946249 hasConceptScore W4282946249C67705224 @default.
• W4282946249 hasConceptScore W4282946249C71924100 @default.
• W4282946249 hasConceptScore W4282946249C98274493 @default.
• W4282946249 hasIssue "12_Supplement" @default.
• W4282946249 hasLocation W42829462491 @default.
• W4282946249 hasOpenAccess W4282946249 @default.
• W4282946249 hasPrimaryLocation W42829462491 @default.
• W4282946249 hasRelatedWork W2156647409 @default.
• W4282946249 hasRelatedWork W2568236141 @default.
• W4282946249 hasRelatedWork W2767471949 @default.
• W4282946249 hasRelatedWork W2767980048 @default.
• W4282946249 hasRelatedWork W2769241338 @default.
• W4282946249 hasRelatedWork W2887887720 @default.
• W4282946249 hasRelatedWork W2981762400 @default.
• W4282946249 hasRelatedWork W3002825748 @default.
• W4282946249 hasRelatedWork W3165064154 @default.
• W4282946249 hasRelatedWork W4251535157 @default.
• W4282946249 hasVolume "82" @default.
• W4282946249 isParatext "false" @default.
• W4282946249 isRetracted "false" @default.
• W4282946249 workType "article" @default.